ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,801 to 2,820 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
ATP and Shock vs Shock Only: All-Cause Shock129 of 1,302

178 of 1,293

-3.9 points

-6.4 to -1.4

2,595NCT02923726

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

ATP and Shock vs Shock Only: All Cause Mortality196 of 1,302

174 of 1,293

1.6 points

-1.1 to 4.3

2,595NCT02923726

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

ATP and Shock vs Shock Only: All-Cause Shock or Death From Any Cause297 of 1,302

322 of 1,293

-2.1 points

-5.4 to 1.2

2,595NCT02923726

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

ATP and Shock vs Shock Only: deaths from any cause196 of 1,302

175 of 1,293

1.5 points

-1.2 to 4.2

2,595NCT02923726

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

ATP and Shock vs Shock Only: serious adverse events633 of 1,302

618 of 1,293

0.8 points

-3.0 to 4.7

2,595NCT02923726

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography4 of 1,290

7 of 1,304

-0.2 points

-0.8 to 0.3

2,594NCT02173379

Absorb IV Randomized Controlled Trial

Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO: deaths from any cause1 of 1,727

0 of 867

0.1 points

-0.4 to 0.3

2,594NCT03537508

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO: serious adverse events99 of 1,727

38 of 867

1.3 points

-0.5 to 3.0

2,594NCT03537508

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization19 of 1,288

8 of 1,303

0.9 points

0.1 to 1.7

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)66 of 1,288

48 of 1,303

1.4 points

-0.1 to 3.1

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Lesion Failure (TLF)64 of 1,288

48 of 1,303

1.3 points

-0.3 to 2.9

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)13 of 1,288

3 of 1,303

0.8 points

0.2 to 1.5

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR5 of 1,288

1 of 1,303

0.3 points

-0.1 to 0.8

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI59 of 1,288

47 of 1,303

1.0 points

-0.6 to 2.5

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)65 of 1,288

48 of 1,303

1.4 points

-0.2 to 3.0

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)67 of 1,288

53 of 1,303

1.1 points

-0.5 to 2.8

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)5 of 1,288

1 of 1,303

0.3 points

-0.1 to 0.8

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)1 of 1,288

1 of 1,303

0.0 points

-0.4 to 0.4

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI59 of 1,288

48 of 1,303

0.9 points

-0.6 to 2.5

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI)58 of 1,288

47 of 1,303

0.9 points

-0.6 to 2.4

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=141"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=141

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02923726-8f443bc4",
        "title": "ATP and Shock vs Shock Only: All-Cause Shock",
        "summary": "129 of 1302 against 178 of 1293; risk difference -3.9 points, 95% interval -6.4 to -1.4; NCT02923726, Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP",
        "record": "/library/comparisons/NCT02923726-8f443bc4",
        "nct_id": "NCT02923726",
        "kind": "outcome",
        "participants": 2595,
        "risk_difference": {
          "value": -0.038586005467226944,
          "lower": -0.06351217283181079,
          "upper": -0.013739993320094145
        },
        "group_1": "129 of 1,302",
        "group_2": "178 of 1,293",
        "difference": "-3.9 points",
        "interval": "-6.4 to -1.4",
        "trial_title": "Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP"
      },
      {
        "id": "NCT02923726-a9c3a4f5",
        "title": "ATP and Shock vs Shock Only: All Cause Mortality",
        "summary": "196 of 1302 against 174 of 1293; risk difference 1.6 points, 95% interval -1.1 to 4.3; NCT02923726, Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP",
        "record": "/library/comparisons/NCT02923726-a9c3a4f5",
        "nct_id": "NCT02923726",
        "kind": "outcome",
        "participants": 2595,
        "risk_difference": {
          "value": 0.01596686874734926,
          "lower": -0.010976762580061902,
          "upper": 0.042897706372076225
        },
        "group_1": "196 of 1,302",
        "group_2": "174 of 1,293",
        "difference": "1.6 points",
        "interval": "-1.1 to 4.3",
        "trial_title": "Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=142",
  "request_id": "EEq7ILKu4ikhaq1X"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?